Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
SYSUCC-CMY-2022-0416
Phase 2 small_molecule active
Quick answer
Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab for Nasopharyngeal Carcinoma is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active